YAP/TAZ suppress drug penetration into hepatocellular carcinoma through stromal activation

K Cho, SW Ro, HW Lee, H Moon, S Han, HR Kim… - …, 2021 - Wiley Online Library
Background and Aims HCC is the most predominant type of liver cancer affecting 800,000
people globally each year. Various small‐molecule compounds targeting diverse oncogenic …
被引用次数：32 相关文章

YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation.

K Cho, SW Ro, HW Lee, H Moon, S Han… - Hepatology …, 2021 - europepmc.org
YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal
Activation. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC …

YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation

K Cho, SW Ro, HW Lee, H Moon… - Hepatology …, 2021 - pubmed.ncbi.nlm.nih.gov
Background and aims HCC is the most predominant type of liver cancer affecting 800,000
people globally each year. Various small-molecule compounds targeting diverse oncogenic …

YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation

K Cho, SW Ro, HW Lee, H Moon, S Han… - …, 2021 - yonsei.elsevierpure.com
Background and Aims: HCC is the most predominant type of liver cancer affecting 800,000
people globally each year. Various small-molecule compounds targeting diverse oncogenic …

YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation

K Cho, SW Ro, HW Lee, H Moon, S Han, HR Kim… - …, 2021 - khu.elsevierpure.com
Background and Aims: HCC is the most predominant type of liver cancer affecting 800,000
people globally each year. Various small-molecule compounds targeting diverse oncogenic …
[HTML] lww.com

[HTML][HTML] YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation

K Cho, SW Ro, HW Lee, H Moon, S Han, HR Kim… - Hepatology, 2021 - journals.lww.com
Chyme Reinfusion Restores the Regulatory Bile Salt–FGF19 Axi... : Hepatology Chyme
Reinfusion Restores the Regulatory Bile Salt–FGF19 Axis in Patients With Intestinal Failure …

YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation

K Cho, SW Ro, HW Lee, H Moon, S Han, HR Kim… - Hepatology, 2021 - journals.lww.com
Conclusions Lenvatinib reduced tumor PD‐L1 level and Treg differentiation to improve anti‐
PD‐1 efficacy by blocking FGFR4. Levels of FGFR4 expression and Treg infiltration in tumor …